Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Handheld Device Can ID Cardiac Dysfunction in Cancer Survivors

Vivio can accurately detect cardiac dysfunction in anthracycline-exposed childhood cancer survivors

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, June 22, 2018 (HealthDay News) -- A novel handheld mHealth platform (Vivio) can accurately detect cardiac dysfunction in anthracycline-exposed childhood cancer survivors, according to a study published online June 21 in Clinical Cancer Research.

Saro H. Armenian, D.O., M.P.H., from the City of Hope in Duarte, Calif., and colleagues conducted a cross-sectional study to compare the accuracy of Vivio and echocardiography for assessment of cardiac function (left ventricular ejection fraction [EF]) in childhood cancer survivors with cardiac magnetic resonance (CMR) imaging. Concurrent evaluation of EF was performed using Vivio, two-dimensional echocardiography, and CMR. One hundred ninety-one consecutive survivors participated in the study. Their median anthracycline dose was 225 mg/m².

The researchers found that echocardiography overestimated mean EF by 4.9 percent; in linear regression analysis, a proportional bias was confirmed when compared with CMR. No difference was seen between mean EF derived from Vivio and CMR (−0.2 percent; P = 0.68). Compared with CMR, the detection of cardiac dysfunction via echocardiography was poor (Echo EF <45 percent: sensitivity, 14.3 percent; Echo EF <50 percent: sensitivity, 28.6 percent). Vivio-based measurements had considerably better sensitivity (EF <45 percent or EF <50 percent: sensitivity, 85.7 percent).

"This accessible technology has the potential to change the day-to-day practice of clinicians caring for the large number of patients diagnosed with cardiac dysfunction and heart failure each year, allowing real-time monitoring and management of their disease without the lag-time between imaging and interpretation of results," the authors write.

Several authors disclosed financial ties, including ownership interests, to biotechnology companies.

Abstract/Full Text (subscription or payment may be required)

Last Updated: